Erythropoietin (EPO) is a hormone that is produced from the kidney inside the human body. EPO biomarkers Market are used to increase the growth of red blood cells in the body by stimulating the bone marrow. Some of the EPO biomarkers available in the market are epoetin alfa, epoetin beta, epoetin zeta, epoetin theta, recombinant human erythropoietin, and darbepoetin alfa. Erythropoietin alfa is used to treat anemia and cancer cells and it increases the count of red blood cells in the body. Erythropoietin is mostly administered as an alternative to iron supplements. Moreover, the erythropoietin biomarkers are used to treat end-stage renal diseases (ESRD), and anemia induced from multiple myeloma, cancer, and AIDS associated anemia.
Major factors contributing to the growth of the global EPO biomarkers market include increasing sedentary lifestyle and faulty dietary habits has increased the prevalence of cancers and chronic kidney diseases in the emerged economies. Moreover, the increasing incidence of end-stage renal disorders and hematological diseases is further increasing the demand for EPO biomarkers. The patent expiration of EPO biomarkers is significantly increasing the introduction of novel EPO biomarkers in the market. However, the lack of quality control testing laboratories in emerging economies such as India and China is a major factor hindering the growth of the market. Improper price capping regulations across the globe is another factor that is significantly responsible in hampering the growth of the global EPO biomarkers market. However, the favorable healthcare regulations in emerged economies such as the U.S. and rising prevalence of chronic diseases such as cancer is expected to fuel the market growth in the near future.